Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) shares were down 5.3% during mid-day trading on Monday . The company traded as low as $16.25 and last traded at $16.32, with a volume of 263,869 shares trading hands. The stock had previously closed at $17.24.

A number of research analysts recently issued reports on AMPH shares. BMO Capital Markets started coverage on shares of Amphastar Pharmaceuticals in a research report on Tuesday, June 28th. They set a “market perform” rating and a $17.00 price target for the company. Needham & Company LLC lowered their price target on shares of Amphastar Pharmaceuticals from $21.00 to $20.00 and set a “buy” rating for the company in a research report on Tuesday, May 10th. Finally, TheStreet raised shares of Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, April 14th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $16.80.

The stock has a market capitalization of $743.08 million and a price-to-earnings ratio of 8285.00. The firm’s 50 day moving average price is $16.35 and its 200-day moving average price is $13.41.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Monday, May 9th. The company reported $0.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.15. During the same period in the previous year, the business posted ($0.01) earnings per share. The business had revenue of $59.40 million for the quarter, compared to analyst estimates of $62 million. The firm’s revenue for the quarter was up 4.4% compared to the same quarter last year. Equities research analysts predict that Amphastar Pharmaceuticals Inc. will post $0.12 earnings per share for the current year.

In related news, Director Richard K. Prins sold 7,500 shares of the firm’s stock in a transaction dated Monday, June 13th. The stock was sold at an average price of $15.94, for a total transaction of $119,550.00. Following the completion of the sale, the director now directly owns 29,086 shares of the company’s stock, valued at approximately $463,630.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO William J. Peters sold 2,297 shares of the firm’s stock in a transaction dated Thursday, June 2nd. The stock was sold at an average price of $16.00, for a total value of $36,752.00. Following the sale, the chief financial officer now directly owns 66,949 shares of the company’s stock, valued at $1,071,184. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Amphastar Pharmaceuticals stock. Russell Frank Co raised its position in Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) by 289.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 83,965 shares of the company’s stock after buying an additional 62,407 shares during the period. Russell Frank Co owned 0.19% of Amphastar Pharmaceuticals worth $1,204,000 as of its most recent filing with the SEC.

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.